BioCentriq, a global cell-based therapy contract development and manufacturing organization (CDMO), reported the successful completion of its latest round of fundraising, securing $29.2 million to accelerate delivery of cell therapies by translating, optimizing, and scaling processes for GMP manufacture.

With this capital, BioCentriq will further accelerate its capabilities to provide end-to-end services for cell therapy development and manufacturing. The funds will be used to enhance BioCentriq’s state-of-the-art facilities, invest in advanced technologies, and expand its team of experts to meet the increasing demand for scalable cell therapy services.

“We are thrilled to announce the successful completion of our latest fundraising round, which reflects the confidence of our investors in BioCentriq’s vision and capabilities,” said James Park, BioCentriq Interim CEO and Chairman of the Board. “This capital injection positions us strongly to continue driving innovation in cell therapy development, enabling our partners to bring transformative treatments to patients around the world.”

The company’s services include process development, manufacturing, and analytical testing to help ensure seamless and efficient development of cell-based therapies for diverse therapeutic areas.